These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 21983457

  • 1. [Administration of dalteparin in reconstructive vascular surgery].
    Pokrovskiĭ AV, Gontarenko VN, Titova MI.
    Angiol Sosud Khir; 2011; 17(2):17-22. PubMed ID: 21983457
    [Abstract] [Full Text] [Related]

  • 2. [Intraoperative administration of low-molecular-weight heparins in reconstructive vascular operations].
    Pokrovskiĭ AV, Demidova VS, Titova MI, Gontarenko VN, Burtseva EA.
    Angiol Sosud Khir; 2008; 14(3):11-7. PubMed ID: 19791426
    [Abstract] [Full Text] [Related]

  • 3. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
    Kovacs MJ, Kearon C, Rodger M, Anderson DR, Turpie AG, Bates SM, Desjardins L, Douketis J, Kahn SR, Solymoss S, Wells PS.
    Circulation; 2004 Sep 21; 110(12):1658-63. PubMed ID: 15364803
    [Abstract] [Full Text] [Related]

  • 4. Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases.
    Pineo GF, Hull RD.
    Eur J Med Res; 2004 Apr 30; 9(4):215-24. PubMed ID: 15210402
    [Abstract] [Full Text] [Related]

  • 5. Heparin and low-molecular-weight heparin.
    Gray E, Mulloy B, Barrowcliffe TW.
    Thromb Haemost; 2008 May 30; 99(5):807-18. PubMed ID: 18449410
    [Abstract] [Full Text] [Related]

  • 6. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
    Prescrire Int; 2005 Feb 30; 14(75):14-5. PubMed ID: 15751168
    [Abstract] [Full Text] [Related]

  • 7. The direct thrombin inhibitor hirudin.
    Greinacher A, Warkentin TE.
    Thromb Haemost; 2008 May 30; 99(5):819-29. PubMed ID: 18449411
    [Abstract] [Full Text] [Related]

  • 8. Humoral coagulation and early complications after allogeneic bone marrow transplantation.
    Nürnberger W, Kruck H, Mauz-Körholz C, Burdach S, Göbel U.
    Klin Padiatr; 1997 May 30; 209(4):209-15. PubMed ID: 9293452
    [Abstract] [Full Text] [Related]

  • 9. Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
    Marmur JD, Poludasu S, Feit A, Battala VR, Cavusoglu E.
    J Invasive Cardiol; 2008 Jul 30; 20(7):323-7. PubMed ID: 18599887
    [Abstract] [Full Text] [Related]

  • 10. [State of the art: low-molecular-weight heparin and beyond].
    Cimminiello C, Casali G, Vitali L.
    Minerva Cardioangiol; 2000 Dec 30; 48(12 Suppl 1):61-5. PubMed ID: 11253343
    [Abstract] [Full Text] [Related]

  • 11. [Thrombocytopenia can be HIT. Heparin treatment can cause low life-threatening thrombocyte levels].
    Själander A, Johansson L, Hillarp A, Bergqvist D, Tengborn L, Svensson P.
    Lakartidningen; 2000 Dec 30; 106(10):682-5. PubMed ID: 19418688
    [No Abstract] [Full Text] [Related]

  • 12. Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
    Gramse CA, Hingorani A, Ascher E.
    J Vasc Nurs; 2001 Jun 30; 19(2):42-9; quiz 50-1. PubMed ID: 11395717
    [Abstract] [Full Text] [Related]

  • 13. High-dose intravenous dalteparin can be monitored effectively using standard coagulation times.
    Wilson JM, Gilbert J, Harlan M, Bracey A, Allison P, Schooley C, Pinto K.
    Clin Appl Thromb Hemost; 2005 Apr 30; 11(2):127-38. PubMed ID: 15821819
    [Abstract] [Full Text] [Related]

  • 14. The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
    Cavusoglu E, Lakhani M, Marmur JD.
    J Invasive Cardiol; 2005 Aug 30; 17(8):416-21. PubMed ID: 16079447
    [Abstract] [Full Text] [Related]

  • 15. Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer.
    Schött U, Nilsson LG, Broman M, Engström M.
    Perfusion; 2010 Jul 30; 25(4):191-6. PubMed ID: 20530518
    [Abstract] [Full Text] [Related]

  • 16. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J, Johnston N, Siegbahn A.
    Am Heart J; 2008 Mar 30; 155(3):493.e1-8. PubMed ID: 18294482
    [Abstract] [Full Text] [Related]

  • 17. Practice guidelines for reversal of new and old anticoagulants.
    Hartman SK, Teruya J.
    Dis Mon; 2012 Aug 30; 58(8):448-61. PubMed ID: 22818559
    [No Abstract] [Full Text] [Related]

  • 18. Management of anticoagulation and platelet inhibition in reconstructive vascular surgery.
    Comerota AJ, Thakur S.
    Vascular; 2008 Aug 30; 16 Suppl 1():S48-54. PubMed ID: 18544305
    [Abstract] [Full Text] [Related]

  • 19. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K, Kovacs MJ, Kahn SR, Wells P, Doucette S, Ramsay T, Clement AM, Khurana R, Mackinnon K, Blostein M, Solymoss S, Kingdom J, Sermer M, Rey E, Rodger M, TIPPS investigators.
    Thromb Haemost; 2007 Jul 30; 98(1):163-71. PubMed ID: 17598009
    [Abstract] [Full Text] [Related]

  • 20. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J, Iqbal O, Cunanan J, Demir M, Wahi R, Clarke M, Adiguzel C, Bick R.
    Int Angiol; 2008 Jun 30; 27(3):176-92. PubMed ID: 18506123
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.